Clovis Oncology Inc expected to post a loss of 48 cents a share - Earnings Preview

Clovis Oncology

01/11/2021 17:00

* Clovis Oncology Inc  CLVS.OQ   CLVS.O  is expected to show a
rise in quarterly revenue when it reports  results on November
3. 
* The Boulder, Colorado-based company is expected to report  a
1.7% increase in revenue to $39.449 million from $38.77 million
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Clovis Oncology Inc is
for a loss of 48 cents per share. For the same quarter last
year, the company reported a loss of 89 cents per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and 2 "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Clovis Oncology
Inc is $5.75​, about 24.7% above​ its last closing price
of $4.33. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 302021   -0.55       -0.56      -0.61     Missed  -8
 Mar. 312021   -0.73       -0.72      -0.64     Beat    10.9
 Dec. 312020   -0.76       -0.77      -1.02     Missed  -32.5​
 Sep. 302020   -0.98       -0.99      -0.89     Beat    10.3
 ​​Jun.        -1.03       -1.04      -1.15     Missed  -10.1
 302020                                                 
 Mar. 312020   -1.24       -1.28      -1.28     Met     -0.1​
 Dec. 312019   -1.67       -1.71      -1.81     Missed  -6
 Sep. 302019   -1.90       -1.89      -1.78     Beat    5.9
 This summary was machine generated November 1 at 17:00 GMT.  All
figures in US dollars unless otherwise stated